Organoids built for predictive relevance and translational insight
When predictive relevance drives experimental outcomes, start with clinically annotated, patient-derived organoids built for consistent, defensible results. These genomically characterized systems support non-animal research approaches and more accurately reflect disease biology, heterogeneity, and treatment response than conventional models, helping scientists make more confident, defensible decisions in drug development and translational studies.
The power of patient-derived organoids
Learn how patient-derived organoid models developed by the Human Cancer Models Initiative (HCMI) capture tumor diversity and support more predictive cancer research.
